Pathalys brings in $105M from Series B Funding Effort

Through a series B fundraising effort, Pathalys Pharma has raised $105 million, which the kidney disease-focused biotech will utilise to advance its top candidate through the latter phases of clinical research.

Upacicalcet, a calcimimetic that may help address secondary hyperparathyroidism (SHPT) in haemodialysis patients, is the business’s main focus. Calcimimetics, which imitate the effects of calcium on tissues for managing problems linked to calcium homeostasis or skeletal integrity, include Sensipar, an authorised SHPT medication from Amgen.

Pathalys began upacicalcet phase 3 studies for SHPT in May with two identical 375-person trials. Patients receiving haemodialysis frequently experience this common, albeit dangerous, side effect of chronic renal disease. According to Pathalys earlier this year, pacicalcet “performed exceptionally well” in late-stage tests conducted in Japan, where it is already licensed for SHPT.said earlier this year.

The biotech stated that the additional funding will be utilised to complete those studies, start the process of getting ready to submit an application for FDA approval, and “accelerate preapproval commercialisation preparations.”